CareDx Signs Agreement With EuroBio Scientific To Divest Lab Products Operations For $170M In Cash; Reports Preliminary Q1 Revenue ~$118M, Up 39% YoY
Benzinga Newsdesk 6 months ago
News
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare
CareDx, Inc. (Nasdaq: CDNA) — The Transplant Company™, a leading precision medicine company focused on the discovery, development, and commercialization of clinically differentiated, high‑value healthcare solutions for transplant patients and caregivers, today announced that it has entered into a definitive agreement to divest its Lab Products business to EuroBio Scientific for cash consideration of $170 million. The transaction has been approved by the boards of directors of both companies. CareDx also announced today preliminary financial results for the first quarter of 2026.
Preliminary First Quarter 2026 Financial Results
- Revenue of approximately $118 million, growth of 39% year-over-year